



Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results

February 27, 2020

WARMINSTER, Pa., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and Year-End 2019 financial results, conference call and webcast for Thursday, March 5, 2020. The schedule for the press release and conference call/webcast are as follows:

- Q4 2019 Press Release: March 5, 2020 at 7:30 a.m. ET
- Q4 2019 Conference Call: March 5, 2020 at 8:45 a.m. ET
- Domestic Dial-In Number: (866) 393-1607
- International Dial-In Number: (914) 495-8556
- Conference ID Number: 5084457

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at www.arbutusbio.com.

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID 5084457.

About Arbutus

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B (HBV) infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit www.arbutusbio.com.

Contact Information

Investors and Media

William H. Collier
President and CEO
Phone: 604-419-3200
Email: ir@arbutusbio.com

Pam Murphy
Investor Relations Consultant
Phone: 604-419-3200
Email: ir@arbutusbio.com



Source: Arbutus Biopharma Corporation